Evidence map›Paper›PMID 33797621›Full record

SynthesisArchives of virology2021

The common risk factors for progression and mortality in COVID-19 patients: a meta-analysis.

Li Zhang, Jie Hou, Fu-Zhe Ma, Jia Li, Shuai Xue, Zhong-Gao Xu

Open access · bronzeAbstract readMeta-Analysis
In one paragraph

Synthesis in Archives of virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Role of C-Reactive Protein in Kidney Diseases.Kidney diseases (Basel, Switzerland) · 2023
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Li ZhangDepartment of Nephrology, The First Hospital of Jilin University, Changchun, 130021, Jilin, People's Republic of China.
Jie HouDepartment of Nephrology, The First Hospital of Jilin University, Changchun, 130021, Jilin, People's Republic of China.
Fu-Zhe MaDepartment of Nephrology, The First Hospital of Jilin University, Changchun, 130021, Jilin, People's Republic of China.
Jia LiDepartment of Nephrology, The First Hospital of Jilin University, Changchun, 130021, Jilin, People's Republic of China.
Shuai Xue *Department of Thyroid Surgery, The First Hospital of Jilin University, Changchun, 130021, Jilin, People's Republic of China. xueshuai@jlu.edu.cn.
Zhong-Gao Xu *Department of Nephrology, The First Hospital of Jilin University, Changchun, 130021, Jilin, People's Republic of China. zhonggao@jlu.edu.cn.ORCID http://orcid.org/0000-0001-8120-3165
Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19), defined by the World Health Organization (WHO), has affected more than 50 million patients worldwide and caused a global public health emergency. Therefore, there is a recognized need to identify risk factors for COVID-19 severity and mortality. A systematic search of electronic databases (PubMed, Embase and Cochrane Library) for studies published before September 29, 2020, was performed. Studies that investigated risk factors for progression and mortality in COVID-19 patients were included. A total 344,431 participants from 34 studies were included in this meta-analysis. Regarding comorbidities, cerebrovascular disease (CVD), chronic kidney disease (CKD), coronary heart disease (CHD), and malignancy were associated with an increased risk of progression and mortality in COVID-19 patients. Regarding clinical manifestations, sputum production was associated with a dramatically increased risk of progression and mortality. Hemoptysis was a risk factor for death in COVID-19 patients. In laboratory examinations, increased neutrophil count, decreased lymphocyte count, decreased platelet count, increased C-reactive protein (CRP), coinfection with bacteria or fungi, increased alanine aminotransferase (ALT) and creatine kinase (CK), increased N-terminal pronatriuretic peptide (NT-proBNP), and bilateral pneumonia in CT/X-ray were significantly more frequent in the severe group compared with the non-severe group. Moreover, the proportion of patients with increased CRP and total bilirubin (TBIL) was also significantly higher in the deceased group than in the survival group. CVD, CKD, sputum production, increased neutrophil count, decreased lymphocyte count, decreased platelet count, increased CRP, coinfection with bacteria or fungi, increased ALT and CK, increased NT-proBNP, and bilateral pneumonia in CT/X-ray were associated with an increased risk of progression in COVID-19 patients. Moreover, the proportion of patients with increased sputum production, hemoptysis, CRP and TBIL was also significantly higher in the deceased group.

Indexed as

BiomarkersComorbidityCOVID-19Disease ProgressionHumansRisk FactorsSARS-CoV-2Severity of Illness IndexBiomarkers

Identifiers

PMID33797621
PMCPMC8017903
OpenAlexW3150431331

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.